Evidence map›Paper›PMID 40069686›Full record

ArticleJournal of nanobiotechnology2025

MXene-based nanosheet for enhanced glioma therapy via photonic hyperthermia to boost the abscopal effect of radioimmunotherapy.

Huan Zhu, Zhaoyuan Zhang, Rong Jiang, Liangfu Xu, Xiangdi Yang, Jie Chen, Zhenning Wang, Xiao Xu, Zhigang Liu

Erratum issuedAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Huan Zhu *Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China.
Zhaoyuan Zhang *Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China.
Rong Jiang *Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China.
Liangfu XuCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China.
Xiangdi YangCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China.
Jie ChenCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China.
Zhenning WangCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China.
Xiao XuCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China. xiaoxu721@smu.edu.cn.
Zhigang LiuCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The 10th Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510280, China. zhigangliu1983@hotmail.com.

Funding

Guangdong Basic and Applied Basic Research Foundation Special Projects (Regional Joint Fund-Key Project) No. 23201910250000400Open Fund of the China Spallation Neutron Source Songshan Lake Science City No. KFKT2023A02the Guangdong Basic and Applied Basic Research Foundation Special Projects (Regional Cultivation Project) No. 2023A1515140032
6 · The paper itself

Abstract

Radiotherapy (RT) effectiveness is limited by low DNA damage in tumor cells, surrounding tissue harm, and tumor radioresistance with active DNA repair. Herein, we have engineered a two-dimensional nanomaterial consisting of MXene nanosheets at its core, coated with gold nanorods and a cisplatin shell, and further modified with polyvinyl alcohol, referred to as APMP. The APMP exploits its distinctive electronic properties and photothermal effects to augment radiosensitivity and impede DNA damage repair mechanisms. In vitro experiments demonstrate that APMP elevates reactive oxygen species (ROS) production to approximately 2.6 times higher than that achieved with radiotherapy alone, thereby significantly enhancing the sensitivity to radiotherapy. Combining APMP with photothermal therapy (PTT) and RT is a promising glioblastoma treatment strategy, achieving tumor destruction via localized hyperthermia and overcoming radioresistance. This approach achieves precise tumor targeting, reducing side effects and enhancing therapeutic response in preclinical models. The novel core-shell design enables potent radiotherapy-specific radiosensitizers that drive immunogenic cell death, enhancing glioblastoma combination immunotherapy. This universal strategy heralds a new era in integrating radiotherapy sensitizers with immunotherapy.

Indexed as

GliomaHyperthermia, InducedNanostructuresRadioimmunotherapyAnimalsBrain NeoplasmsCell Line, TumorCisplatinCombined Modality TherapyGoldHumansMiceNanotubesNitritesPhotothermal TherapyRadiation-Sensitizing AgentsCisplatinGoldMXeneNitritesRadiation-Sensitizing AgentsReactive Oxygen SpeciesTransition ElementsAbscopal effectMxenePhotothermal therapyRadiosensitizer

Identifiers

PMID40069686
PMCPMC11895210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.